Skip to main content

Table 1 HR, and odds ratios obtained with the NMA for duration of PFS and OR, all relative to Pac/Carb treatment

From: Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

 

Pac/Carb

Gem/Cis*

Pem/Cis*

Gefitinib**

PFS HR (95% CrI)

1

0.92 (0.80; 1.04)

0.88 (0.74; 1.05)

0.43 (0.34; 0.53)

OR (Odds ratio) (95% CrI)

1

1.16 (0.93; 1.44)

1.64 (1.15; 2.27)

4.63 (3.01; 6.98)

  1. HR:Hazard ratio, PFS: progression free survival, OR: objective response Data retrieved from UK NMA [6] 95% CrI: 95% credibility interval, * determined for general patient group with advanced NSCL and first-line treatment, ** determined for EGFR M+ patients.
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us